Chinook Therapeutics (KDNY) Stock Price, News & Analysis

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chinook Therapeutics in the last twelve months. There are currently 10 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" KDNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KDNY, but not buy additional shares or sell existing shares.
View KDNY analyst ratings or view top-rated stocks.

11 brokers have issued 1 year price objectives for Chinook Therapeutics' stock. Their KDNY share price targets range from $32.00 to $42.00. On average, they anticipate the company's share price to reach $37.25 in the next twelve months. This suggests that the stock has a possible downside of 7.8%.
View analysts price targets for KDNY or view top-rated stocks among Wall Street analysts.

Chinook Therapeutics, Inc. (NASDAQ:KDNY) posted its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.03. The company had revenue of $1.83 million for the quarter, compared to analyst estimates of $0.14 million. Chinook Therapeutics had a negative trailing twelve-month return on equity of 58.28% and a negative net margin of 4,199.93%. Chinook Therapeutics's revenue was down 32.2% on a year-over-year basis.

Principal Healthcare Innovators ETF holds 9,493 shares of KDNY stock, representing 0.72% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR).